Dyslipidaemia
Three documents: the ACC/AHA 2026 US guideline, and the ESC/EAS 2019 European guideline with its 2025 focused update. Both now use LDL-C goals.
Where they agree and differ
| ACC/AHA 2026 | ESC/EAS 2019 + 2025 | |
|---|---|---|
| Risk tool | PREVENT (10-year ASCVD) | SCORE2 / SCORE2-OP |
| Very-high-risk goal | <55 mg/dL (very-high-risk ASCVD) | <55 mg/dL (1.4 mmol/L) + ≥50% fall |
| High-risk goal | <70 mg/dL | <70 mg/dL (1.8 mmol/L) + ≥50% fall |
| Moderate risk | <100 mg/dL | <100 mg/dL (2.6 mmol/L) |
| Lp(a) | Once in every adult; high ≥125 nmol/L (≥50 mg/dL) | Once in a lifetime; >50 mg/dL is a risk enhancer |
| Add-on order | Ezetimibe → PCSK9 mAb / bempedoic acid / inclisiran | Ezetimibe → PCSK9 inhibitor; bempedoic acid if statin-intolerant |